NETSPOT KIT

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

OXODOTREOTIDE

Inapatikana kutoka:

NOVARTIS PHARMACEUTICALS CANADA INC

ATC kanuni:

V09I

INN (Jina la Kimataifa):

TUMOUR DETECTION

Kipimo:

40MCG

Dawa fomu:

KIT

Tungo:

OXODOTREOTIDE 40MCG

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Schedule C

Eneo la matibabu:

ROENTGENOGRAPHY

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0161570001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2019-07-03

Tabia za bidhaa

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
NETSPOT®
40 microgram kit for the preparation of gallium (
68
Ga) oxodotreotide for injection
Diagnostic Radiopharmaceutical Kit
Novartis Pharmaceuticals Canada Inc.
700 Saint-Hubert St., Suite 100
Montreal, Quebec
H2Y 0C1
Date of Initial Authorization:
Jul 03, 2019
Date of Revision:
Feb 28, 2024
Submission Control Number: 282568
NETSPOT is a registered trademark
_NETSPOT® (kit for the preparation of gallium (_
_68_
_Ga) oxodotreotide injection) _
_Page 2 of 28_
RECENT MAJOR LABEL CHANGES
4 Dosage and Administration, 4.4 Administration
06/2021
4 Dosage and Administration, 4.7 Instructions for Preparation and
Use
06/2021
4 Dosage and Administration, 4.8 Radiation Dosimetry
06/2021
7 Warnings and Precautions
06/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
..............................................................................................................................4
1.2
Geriatrics
..............................................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................................
4
4
DOSAGE AND ADMINISTRATION
.............................................................................................
4
4.1
Dosing Considerations
...........................................................